Also known as bepecin, pl 14736, body protection compound 157, gastric pentadecapeptide, bpc · Wikipedia
BPC-157 (Body Protection Compound-157, also designated PL 14736 in the Pliva clinical program) is a synthetic 15-amino-acid pentadecapeptide originally derived from a putative cytoprotective fragment of human gastric juice protein. It is widely marketed as a 'healing peptide' associated with injury recovery, tendon/ligament repair, gut protection, and joint health. The overwhelming majority of efficacy evidence derives from rodent models, predominantly from a single research group led by Predrag Sikirić at the University of Zagreb, who have published several hundred preclinical papers describing protective effects on the gastrointestinal tract, musculoskeletal system, and central nervous system. A small early-2000s human IBD program by Pliva (PL-14736) reached Phase II but was never advanced to approval, and BPC-157 remains a research chemical without any FDA-approved indication. WADA prohibits its use in athletic competition (Category S0).
4–8 wk
typical
cycle
250 µg
daily
dose
Sub-Q
primary
route
Animal
studies
only
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
BPC-157 has no single defined receptor and instead appears to act through multiple repair-related pathways characterized almost entirely in rodent models. The most reproducible mechanism is upregulation of VEGFR2-Akt-eNOS signalling, producing pro-angiogenic effects in muscle, tendon, ligament, and gut models (Hsieh et al.
Pharmacokinetic properties
Half-life
Approximately 4–6 hours after subcutaneous administration in rodent models; systemic exposure after oral dosing is poorly characterized in humans.
Routes
subcutaneous · intramuscular · oral · topical · intranasal
Bioavailability
Manufacturer and vendor literature describe BPC-157 as 'gastric-stable,' and rodent oral studies demonstrate pharmacological activity by that route, but no rigorous human oral PK or bioavailability data exist. Most published efficacy data are from rodent intraperitoneal or intramuscular dosing; commercial human use is overwhelmingly subcutaneous.
Amino-acid sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Use & research dosing
There is no FDA-approved human dose. Commonly reported in research and self-experimentation protocols at roughly 200–500 mcg subcutaneously once or twice daily, frequently administered near the site of injury, in cycles of 4–8 weeks with washout. These figures are extrapolated by allometric scaling from rodent studies (typically 10 µg/kg or 10 ng/kg in Sikirić-group experiments) and are not derived from validated human pharmacokinetic or dose-finding work. Oral protocols in the 250–500 µg/day range are also reported; intestinal absorption in humans has not been formally measured, despite manufacturer 'gastric-stable' marketing. Topical and intranasal routes are described anecdotally with no PK validation. All dosing should be considered exploratory.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Despite enormous popular use, virtually all efficacy data for BPC-157 are preclinical (rodent) and over 80% of records derive from the Sikirić group in Zagreb (https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/). The single human program of record — Pliva's PL-14736 for inflammatory bowel disease — established tolerability but was never advanced to Phase III, and Pliva later dropped the program (https://pubmed.ncbi.nlm.nih.gov/17186181/). FDA classified BPC-157 as a Category 2 (significant safety risk) bulk drug substance for 503A compounding in 2023, with PCAC review of additional bulk-substance nominations scheduled for 2026. The 'stomach-stable' marketing claim for oral BPC-157 has not been validated in humans.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
medium
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.